Equities research analysts at Citizens Jmp initiated coverage on shares of Hinge Health (NYSE:HNGE - Get Free Report) in a research note issued on Monday, MarketBeat reports. The brokerage set a "strong-buy" rating and a $58.00 price target on the stock. Citizens Jmp's price objective points to a potential upside of 25.60% from the company's previous close.
Other equities analysts have also recently issued reports about the stock. KeyCorp raised their target price on shares of Hinge Health from $45.00 to $60.00 and gave the company an "overweight" rating in a research note on Monday. William Blair began coverage on shares of Hinge Health in a research note on Monday, June 16th. They issued an "outperform" rating for the company. Piper Sandler began coverage on shares of Hinge Health in a research note on Monday, June 16th. They issued an "overweight" rating and a $41.00 price objective for the company. Stifel Nicolaus began coverage on shares of Hinge Health in a research note on Monday, June 16th. They issued a "buy" rating and a $48.00 price objective for the company. Finally, Truist Financial began coverage on shares of Hinge Health in a research note on Monday, June 16th. They issued a "buy" rating and a $48.00 price objective for the company. One analyst has rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $49.36.
Check Out Our Latest Analysis on Hinge Health
Hinge Health Stock Performance
Shares of HNGE stock traded down $0.77 on Monday, hitting $46.18. 258,737 shares of the stock traded hands, compared to its average volume of 1,000,045. Hinge Health has a 52 week low of $33.42 and a 52 week high of $52.16.
About Hinge Health
(
Get Free Report)
Our vision is to build a new health system that transforms outcomes, experience and costs by using technology to scale and automate the delivery of care. Hinge Health leverages software, including AI, to largely automate care for joint and muscle health, delivering an outstanding member experience, improved member outcomes, and cost reductions for our clients.
See Also

Before you consider Hinge Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hinge Health wasn't on the list.
While Hinge Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.